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Abstract
Insertional mutations leading to expansion of the octarepeat domain of the prion protein (PrP) are directly linked to prion
disease. While normal PrP has four PHGGGWGQ octapeptide segments in its flexible N-terminal domain, expanded forms
may have up to nine additional octapeptide inserts. The type of prion disease segregates with the degree of expansion.
With up to four extra octarepeats, the average onset age is above 60 years, whereas five to nine extra octarepeats results in
an average onset age between 30 and 40 years, a difference of almost three decades. In wild-type PrP, the octarepeat
domain takes up copper (Cu2+) and is considered essential for in vivo function. Work from our lab demonstrates that the
copper coordination mode depends on the precise ratio of Cu2+ to protein. At low Cu2+ levels, coordination involves
histidine side chains from adjacent octarepeats, whereas at high levels each repeat takes up a single copper ion through
interactions with the histidine side chain and neighboring backbone amides. Here we use both octarepeat constructs and
recombinant PrP to examine how copper coordination modes are influenced by octarepeat expansion. We find that there is
little change in affinity or coordination mode populations for octarepeat domains with up to seven segments (three inserts).
However, domains with eight or nine total repeats (four or five inserts) become energetically arrested in the multi-histidine
coordination mode, as dictated by higher copper uptake capacity and also by increased binding affinity. We next pooled all
published cases of human prion disease resulting from octarepeat expansion and find remarkable agreement between the
sudden length-dependent change in copper coordination and onset age. Together, these findings suggest that either loss
of PrP copper-dependent function or loss of copper-mediated protection against PrP polymerization makes a significant
contribution to early onset prion disease.
Citation: Stevens DJ, Walter ED, Rodrı´guez A, Draper D, Davies P, et al. (2009) Early Onset Prion Disease from Octarepeat Expansion Correlates with Copper
Binding Properties. PLoS Pathog 5(4): e1000390. doi:10.1371/journal.ppat.1000390
Editor: Umberto Agrimi, Istituto Superiore di Sanita`, Italy
Received November 12, 2008; Accepted March 20, 2009; Published April 17, 2009
Copyright:  2009 Stevens et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: National Institutes of Health Grant GM065790 to GM. PD was supported by a studentship from the BBSRC (Biotechnology and Biological Sciences
Research Council) of the United Kingdom.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: glennm@chemistry.ucsc.edu
Introduction
Prion diseases are infectious neurodegenerative disorders that
arise from accumulation of PrPSc (scrapie conformer), a misfolded
form of the normal cellular prion protein (PrPC) that is found
ubiquitously throughout the central nervous system [1–3]. PrPC is
a GPI anchored glycoprotein possessing a largely a-helical C-
terminal domain and a flexible N-terminal domain (Figure 1).
Within the N-terminal domain are four tandem copies of the
octapeptide repeat (octarepeat) sequence PHGGGWGQ. Approx-
imately 15% of human prion diseases are inherited [4]. The
known disease-causing mutations are either point mutations,
located primarily in the C-terminal domain, or insertions of one to
nine extra octarepeats resulting in expansion of the N-terminal
domain [5]. Interestingly, with octarepeat expansion disease,
progression is determined by the number of repeat inserts. With
one to four extra octarepeats, the average onset age is 64 years,
whereas five to nine extra octarepeats results in an average onset
age of 38 years, a difference of almost three decades [5].
Octarepeat (OR) expansions alter the properties of PrP and its
interactions with cellular components. When expressed in various
cell lines, PrP with additional repeats displays detergent insolubil-
ity, resistance to proteinase K digestion similar to PrPSc [6], altered
cell surface expression [7], and hindered export to the cell surface
[8]. Moreover, compared to wild-type, expanded PrP exhibits a
stronger association with the cell membrane and a larger
proportion of partially glycosylated forms [9]. Transgenic mice
expressing insert mutants of PrP develop prion disease and show
accumulation of detergent-insoluble, protease-resistant PrP in the
brain [10,11]. Although injection of brain homogenate from these
transgenic mice is not infectious, brain suspensions from humans
with insert mutations can transmit disease to monkeys and
chimpanzees [12–14]. Moreover, in vitro assays show that
recombinant protein containing insert mutations forms amyloid
fibrils faster than wild-type [15]. Truncated forms of the protein
with extra octarepeats show irreversible self association and, unlike
wild-type, can bind PrPSc [16]. Full length mouse PrP with
expanded OR domains shows an altered folding landscape that
reduces the propensity for amyloid formation [17].
After treatment with proteinase K, aggregated PrPSc typically
retains an intact protease-resistant core region, which includes
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the protein’s C-terminal domain, and remains capable of
propagating disease [2,18]. The OR region is located outside
of this core portion of the protein and is cleaved away by
proteinase K. Octarepeat inserts are therefore the only known
disease-causing mutations occurring outside the minimal infec-
tious PrPSc substructure. This suggests that either disease
propagation and mechanisms underlying prion-mediated neuro-
degeneration are separable or, alternatively, that disease resulting
from octarepeat expansions is distinct from other inherited prion
diseases.
A notable feature of the octarepeat domain is that it takes up
copper ions (Cu2+) with an affinity that approximately matches
extracellular copper concentrations in the brain [19,20]. Although
the specific function of PrPC is not yet known, the demonstrated
interaction with copper suggests a number of possibilities,
including protection against Cu2+ mediated oxidative stress,
copper transport and copper dependent cellular signaling [21–
23]. In vitro cell culture studies show that Cu2+ stimulates PrP
endocytosis [24], but this process is quenched in cells expressing
insert mutations of nine extra repeats [25]. The way in which PrP
coordinates Cu2+ depends on the ratio of copper to protein
(Figure 1) [26]. At low copper occupancy, the OR domain wraps
around a single Cu2+ coordinating through multiple His side
chains. At high occupancy, each HGGGW segment within an
octapeptide coordinates a single Cu2+ through the His side chain
and deprotonated amides of the following two Gly residues [27].
These coordination modes are referred to as component 3 and
component 1, respectively [26].
Previous studies examined the biophysical properties of
expanded octarepeat domains with emphasis on either the rate
of amyloid production or its uncomplexed backbone conforma-
tion [16,17,28]. To our knowledge, however, none of these
studies has identified a quantitative link between octarepeat length
and age of disease onset. Here we use electron paramagnetic
resonance (EPR) and affinity studies to examine PrP N-terminal
constructs and full-length protein to examine how copper
coordinates in the octarepeat domain as a function of domain
length. We identify a sharp, length-dependent threshold with
regard to coordination mode and affinity. Next, we survey all
reported cases of human prion disease resulting from octarepeat
expansion and examine age of onset as a function of domain
length. We find a remarkable agreement between alteration in
copper coordination properties and octarepeat inserts associated
with early onset disease.
Results
EPR of Wild-Type and Octarepeat Expanded PrP
Polypeptide constructs corresponding to wild-type and octar-
epeat insert mutations of up to nine total ORs (Table 1) were
synthesized and examined by EPR. Following our previous
studies, each construct begins with the pentapeptide segment
corresponding to residues 23–27 from PrP, to improve solubility in
aqueous solution, and is N-terminally acetylated to prevent
spurious Cu2+ coordination. Figure 2 shows EPR obtained from
each OR domain construct in equilibrium with 3.0 equivalents of
Cu2+. Hyperfine splittings in the parallel region of the spectra are
diagnostic for the different binding modes, as indicated. The 4 OR
construct, corresponding to wild-type, exhibits both component 1
and component 3 coordination. However, with increasing length
of the OR domain, the equilibrium distribution shifts to favor
predominantly component 3 coordination.
To determine the relative concentrations of the different
binding modes for each construct, we used non-negative least
squares (NNLS) fitting to a set of well characterized basis spectra,
as previously described [19]. Figure 3A shows that when the 4 OR
construct is titrated with Cu2+, the populations shift systematically
depending on the specific Cu2+ concentration. Initially, compo-
nent 3 dominates, but beyond 1.0–1.5 equivalents, component 3
diminishes and is replaced by component 1. There is also a low
concentration of component 2 (2-His coordination), but this
intermediate species is relatively minor. The experiment was
repeated for all the expanded OR constructs, and the results for
component 3 are shown in Figure 3B. With 4–7 total ORs (i.e.,
zero to three inserts), the behavior is much like wild-type, reaching
a maximum of component 3 at approximately 1.0–1.5 equivalents
Cu2+. In contrast, the 8 OR construct (four inserts) exhibits
persistent component 3 coordination that reaches a maximum at
approximately 2.0–2.5 equivalents. For the 9 OR construct, the
maximum is shifted to yet higher Cu2+ concentration reaching a
maximum at 3.0–3.5 equivalents. In addition to changes in the
location of the maximum, there is a shift in the amount of Cu2+
bound in the component 3 mode. For 4–7 ORs, the maximum is
approximately 1.0 equivalents. However, for 8 and 9 ORs, 1.5–2.0
equivalents bind in the component 3 mode.
Titrations were also performed with full-length wild-type
recombinant PrP (rPrP) and rPrP containing five extra OR
segments to give nine total (rPrP+5OR). Titrations with full-length
protein require accounting of both OR binding and non-OR
binding (involving two His residues between the octarepeat
domain and the folded C-terminus), as shown in Figures 3C and
3D [29]. With 2.0 equivalents of Cu2+, rPrP shows approximately
equal populations of component 3 and non-OR coordination, at
1.0 equivalent each. At higher copper concentrations, component
3 coordination decreases, followed by an increase in component 1
coordination. The behavior of rPrP closely parallels that of the 4
OR construct in Figure 3A, except that component 3 coordination
reaches its peak between 2.0–3.0 equivalents of Cu2+ since this
coordination mode competes with non-OR binding. The titration
of rPrP+5OR, shown in Figure 3D, exhibits a remarkable
persistence of component 3 coordination. At 5.0 equivalents of
Cu2+, component 3 remains the dominant species. In contrast,
component 3 in wild-type at 5.0 equivalents Cu2+ accounts for
only a small fraction (approximately 10%) of the total copper
bound species. The shift in the persistence of component 3
coordination is shown in Figure 3E where the maximum of
component 3 coordination (derived from the data in Figure 3B) is
plotted against OR length. Taken together, these experiments with
both OR polypeptides and full-length rPrP show that expanded
Author Summary
Prion diseases are neurodegenerative disorders involving
the prion protein, a normal component of the central
nervous system. An unusual class of inherited mutations
giving rise to prion disease involves elongation of the so-
called octarepeat domain, near the protein’s N-terminus.
Research from our lab and others shows that this domain
binds the micronutrient copper, an essential element for
proper neurological function. We investigated how octar-
epeat elongation influences copper binding by examining
both the molecular features and the binding equilibrium.
We find that elongation beyond a specific threshold, which
confers profound early onset disease, gives rise to
concomitant changes in copper uptake. The remarkable
agreement between onset age and altered copper binding
points to loss of copper protein function as significant in
prion neurodegeneration.
Prion Octarepeat Expansion and Copper
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OR domains exhibit a dramatic shift at eight or more repeats that
greatly favors multiple His component 3 coordination relative to
wild-type.
Copper Dissociation Constants of Wild-Type and
Octarepeat Expanded PrP
Component 3 dissociation constants were measured using a
competition assay developed by our lab [19]. Copper binding
chelators with known dissociation constants were added to
solutions containing OR constructs, along with substoichiometric
amounts of Cu2+. Decomposition of the resulting EPR spectra
reveals the concentration ratios of Cu2+ bound to OR construct vs
chelator. By working at low copper concentration, we ensure that
OR constructs coordinate exclusively as component 3, and this is
further verified by lineshape analysis of the EPR spectra. We
performed independent measurements with the chelators penta-
glycine and oxidized glutathione (two glutathione tripeptides
linked through a disulfide bond). Kd values for Cu
2+ are known for
each chelator and are similar to the previously determined
dissociation constant for wild-type component 3 [30,31]. More-
over, these chelators bind Cu2+ as a 1:1 complex, which simplifies
the determination of equilibrium constants. The results, as a
function of OR length, are reported in Figure 4. For wild-type with
four OR segments, the Kd is approximately 10
210 M, consistent
with our previous results [19]. However, for eight and nine OR
constructs, Kd decreases approximately by a factor of 10. There is a
systematic difference between oxidized glutathione and pentagly-
cine, with the latter reporting lower Kd values. Considering the
more conservative results from oxidized glutathione, the affinity
Figure 1. Schematic of PrP(23–231) showing placement of the octarepeat region within the flexible N-terminal domain (23–120).
Wild-type PrP has four repeats, as indicated by the octarepeat sequence. Low copper occupancy favors component 3 coordination; high copper
occupancy favors component 1. Mutations involving insertion of extra (1–9) octarepeats are pathogenic. Other indicated PrP features are the C-
terminal b-strands, helical segments (H1–H3), disulfide bond, GPI anchor, and N-linked glycans (ovals).
doi:10.1371/journal.ppat.1000390.g001
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for Cu2+ with component 3 coordination is at least tenfold higher
in expanded OR domains with eight or more repeat units.
Octarepeat Expansion Disease in Humans
Insertions of extra repeats in humans causes prion disease but
the course of disease depends on the specific length of the OR
domain. Analyses of case studies find consistently that individuals
with insertions of five or more ORs often develop symptoms in
their 30 s, approximately three decades younger than most
instances of sporadic or inherited prion disease [5,32]. To
compare the correlation between OR length and onset age to
our biophysical findings, we examined all reported case studies of
prion disease arising from OR insertions. Data from Croes et al.
[32] and Kong et al. [5], as well as several new case studies were
pooled (Table 2). Together, the data of Table 2 represent 31
reports covering approximately 30 families and 108 individuals.
Entries are ordered with respect to the number of insertions and,
along with each entry, are the range for the age of onset, disease
duration and pathology with regard to PrP associated plaques.
Many cases that examined tissue pathology identified plaques
(although in many instances it was not clear whether reported
plaques were amyloid).
To examine these data more closely, we plotted the age of onset
for each individual case against the number of OR insertions in
Figure 5A. The red horizontal line is at 55.5 years (see below). All
cases up to four OR inserts are above this line and 96% of the
cases of five or more OR inserts are below the line. Although there
is significant scatter in reported onset age for each specific OR
length, the dramatic shift to early onset disease between four and
five inserts is apparent. Figure 5B presents the same data as
parallel boxplots, with sample sizes (number of cases) in each
boxplot given at the top of the graph. An overall F test provided
strong evidence of differences between the mean onset ages for
different numbers of repeats (p-value 2.8e-14) [33]. The results for
all pairwise comparisons are summarized in Figure 5C; cells in
blue correspond to significant pairwise differences at a family-wise
error rate of 5%. The results are consistent with the existence of
two groups, one made of individuals with 1 to 4 OR inserts and
another made of individuals with 5 to 8 inserts. The three patients
with 9 repeats did not show a significant difference with any of the
other groups; this is due to the small sample size in that group.
These results were further supported by an analysis via
regression trees and cubic regression (see Protocol S1). Classifica-
tion and regression trees (CART) [34] introduce binary cuts in the
predictor variable (in this case, number of OR insertions) in a way
that maximizes the distance (measured in terms of the outcome
variable, in this case onset age) between the two groups, with cross-
validation to ensure that spurious splits are not identified. When
CART was applied to our data, a single split was found, dividing
the data set into two groups: patients with 1 to 4 OR inserts (mean
onset age of 64.4 years) and patients with 5 to 9 inserts (mean onset
age of 37.9 years, which clearly differs from 64.4 years by an
amount which is large in clinical/biological terms). Similarly, all
non-constant terms in a cubic regression of onset age on number
of repeats were highly significant (p,0.0001), and the overall F-
test for comparing the cubic model to a constant-age-of-onset
model had a p-value of 4.4e-15. These results confirm a
Figure 2. EPR spectra of octarepeat constructs in equilibrium with 3.0 equivalents of Cu2+. With four and six octarepeats, the spectra are
nearly equivalent and show a mixture of component 1 and component 3 coordination. For longer octarepeat domains, there is a progressive shift to
favor component 3 coordination.
doi:10.1371/journal.ppat.1000390.g002
Table 1. Peptide Sequences.
Ac-KKRPK(PHGGGWGQ)4 corresponding to PrP(23–27,60–91)
Ac-KKRPK(PHGGGWGQ)6
Ac-KKRPK(PHGGGWGQ)7
Ac-KKRPK(PHGGGWGQ)8
Ac-KKRPK(PHGGGWGQ)9
doi:10.1371/journal.ppat.1000390.t001
Prion Octarepeat Expansion and Copper
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nonconstant relationship between the number of repeats and the
onset age in the population of individuals similar to those in our
data set.
CART was also employed to find an optimal onset-age
separator between the group of low (1–4) and high (5–9) number
of OR inserts (horizontal red line in Figure 5A). For this purpose,
Figure 3. Copper coordination properties as a function of octarepeat domain length. (A) Relative populations of components 1 and 3 in
the wild-type octarepeat segment (four repeats). The x-axis reflects the total bound Cu2+ equivalents, while the y-axis is for each individual binding
component. Component 3 is at a maximum at 1.0–1.5 equivalents bound. (B) Component 3 populations in octarepeat sequences of increasing
length. Beyond a threshold of seven repeats, component 3 becomes persistent. (C,D) Component populations in wild-type rPrP and rPrP+5OR,
respectively. (E) Persistence of component 3 as measured by the location of the respective maxima from (B).
doi:10.1371/journal.ppat.1000390.g003
Prion Octarepeat Expansion and Copper
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we treated the group membership as a dependent binary variable
and used onset age as the independent variable; the optimal
separator between the groups corresponded to an age of 55.5
years.
Disease duration and OR number are also related in a manner
that is significant both statistically and clinically/biologically. In
our analysis, duration rose almost monotonically from a mean of
0.4 years for one OR insert to a mean of 10.9 years for seven
inserts, and then fell to a mean of 2.3 years for nine inserts
(ANOVA p-value 7.3e-08 with log(duration) as the outcome;
comparison of all pairs of means with multiplicity adjustment
supported both the rise and fall just mentioned (see Protocol S1);
p-value of 2.7e-06 from a cubic regression of log(duration) on OR
number, testing the overall cubic model against a null model of no
relationship; 27 cases set aside for missing duration data;
additional analyses provided in Protocol S1). For cases of up to
seven OR inserts, our results are consistent with those of Croes et
al., who identified a strictly monotonic increase in survival time for
individuals with more OR inserts [32]. For these cases, we cannot
determine whether this strong positive relationship is a direct
consequence of the specific PrP sequence or, alternatively, is due
to older individuals succumbing more quickly to disease. However,
a recent study of sporadic Creutzfeldt-Jakob disease cases found
that young individuals who developed symptoms below the age of
50 lived almost three times longer than those who developed
disease after 50 [35]. Moreover, in the younger group, disease
duration was not influence by specific PrP genotype. As noted, our
analysis reveals an interesting reversal of the general trend for
cases of eight or more OR inserts: despite early onset disease, these
individuals exhibit short disease duration more consistent with
those who developed symptoms later in life. From the perspective
of Cu2+ uptake, 12 repeats, corresponding to eight inserts, would
likely be the threshold for 3.0 equivalents of component 3
coordination (four His for each of the three Cu2+ ions). It is
possible that PrP with more than eight OR inserts exerts a rapid
rate of neurodegeneration, perhaps due to yet further alterations in
copper binding, that cannot be overcome even in youthful
individuals.
The most striking relationship with OR insert number we
identified is the age of onset, which shows a sudden drop between
four and five inserts from 64.4 years to 37.9 years. Figure 5D
compares the average onset age and standard deviation, as a
function of OR length, to Cu2+ binding properties. As developed
above, the longest OR expansions favor component 3 coordina-
tion and resist component 1. Thus, component 1 coordination
serves as a convenient measure of altered Cu2+ binding properties.
Figure 5D shows the relative population of component 1
coordination for each OR construct, as derived from our copper
titrations above, superimposed on the average age of onset. For
wild-type and expansions involving up to seven ORs (three inserts
beyond wild-type), component 1 coordination is dominant for both
3.0 and 4.0 equivalents Cu2+. However, at eight and nine ORs
(four and five inserts, respectively), the population of component 1
coordination drops precipitously. For example, at 3.0 equivalents
Cu2+, component 1 coordination is nearly 100% for three inserts
and drops to approximately 25% for five inserts. Experimental
challenges with solid phase synthesis and protein expression
prohibited the study of yet longer OR sequences in either
polypeptide constructs or full-length protein, respectively; howev-
er, the trend to favor component 3 for long inserts is clear and
would not reverse for six OR inserts and beyond. Thus, Cu2+
coordination shows a transition between four and five inserts,
coincident with the OR length that correlates with early onset
prion disease.
Discussion
The wild-type OR domain with four repeats responds to
increasing copper concentrations by transitioning from component
3 to component 1 coordination. Our data show that this process is
preserved in longer OR domains up to seven total PHGGGWGQ
repeats. However, for eight repeat segments (four inserts beyond
wild-type) and beyond, this transition is significantly inhibited. The
biophysical basis for this likely arises from the number of repeats
required for component 3 coordination. As demonstrated in our
previous work, component 3 involves coordination of approxi-
mately four His side chains from adjacent octarepeat segments. If
four repeats are required, then OR domains of up to seven total
repeats may only take up a single Cu2+ in the component 3
binding mode, as observed. However, eight total repeats allows for
two equivalents of component 3 coordination. Thus, higher
copper levels are required to drive the transition to component 1
coordination. These arguments based on the stoichiometric ratio
of OR segments to copper are straightforward. However, an
unexpected finding is that expanded OR domains with more than
eight repeats exhibit an approximate 10-fold increase in Cu2+
binding affinity. This affinity shift, in concert with His side chain
counts favoring two equivalents of component 3, contributes to the
decrease in component 1 coordination for OR domains with four
or more inserts beyond wild-type.
To gain insight into the three-dimensional characteristics of PrP
with an expanded OR domain interacting with Cu2+, we
performed structure calculations using distance restraints tethering
four adjacent repeat His side chains to a single copper ion. We
examined PrP with eight repeats and two copper equivalents. The
C-terminal domain coordinates are from NMR studies. Other
than Cu2+-imidazole distances, the OR domain was left
unrestrained during energy minimization. The resulting structure
is shown in Figure 6. (Non-octarepeat Cu2+ are omitted and
approximately 40 residues on the N-terminal side of the first
repeat are not shown.) His imidazoles arrange with an approx-
imate tetrahedral geometry around each copper center. As
expected, the expanded OR domain readily takes up two Cu2+
with a relaxed backbone conformation. Also, with eight total
Figure 4. Component 3 dissociation constants for different OR
lengths. Values were determined from competition studies with
oxidized glutathione or pentaglycine.
doi:10.1371/journal.ppat.1000390.g004
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repeat segments, the OR domain comprises a significant fraction
of the total protein. Although each copper center carries a divalent
positive charge, the rest of the 64 amino acids within the expanded
OR domain are uncharged and thus comprise a significant
hydrophobic domain. PrP with OR inserts show a strong
propensity to form aggregates and amyloid. The enhanced
hydrophobicity of the N-terminal domain may facilitate interac-
tions between PrPC copies, thus promoting the amyloid assembly
process.
To explore the effect of OR inserts on amyloid formation,
Dong et al. developed a chimeric Sup35 yeast protein, in which
PrP octarepeats replaced the endogenous repeat sequences [28].
Amyloid fibers assembled spontaneously from chimeras contain-
ing both 4 and 8 repeats but, in unseeded reactions, the lag
time was substantially shorter for the chimera with the longer
OR domain. Interestingly, when Cu2+ was added in proportion
to the number of repeats in each chimera, the lag time
decreased in the 4 OR construct but increased in the 8 OR
construct. Leliveld et al. examined glutathione-S transferase
(GST) fusion proteins onto which OR domains of varying
length were grafted to the protein C-terminus [16]. Longer OR
constructs exhibited enhanced multimerization and, at a
threshold of 10 ORs, an ability to directly bind PrPSc. Copper
promoted multimerization in both short and long OR
constructs, but the longer OR domains also exhibited
irreversible aggregation in the absence of copper. In contrast,
Table 2. Reported Cases of Extra Repeat Disease.
Reference
(First Author)
Number of Inserted Octarepeats
(Number of Cases) Onset Age (Years) Duration Cerebellar Plaques
Laplanche [47] 1(1) 73 4 mo —
Pietrini [48] 1(2) 58/64 5/6 mo Isolated plaque-like deposits
Van Harten [49] 2(1) 61 7 yr —
Croes [32] 2(1) 59 .10 yr —
Grabson-Frodl [50] 3(1) 69 4 mo Ovoid/round plaque-like deposits
Nishida [51] 3(1) 68 3 yr —
Laplanche [47] 4(1) 82 4 mo —
Isozaki [52] 4(1) 62 — PrP plaques
Campbell [53] 4(1) 56 2 mo PrP patches
Rossi [54] 4(1) 65 6 mo Dotted PrP deposits
Yanagihara [55] 4(1) 56 5 mo —
Goldfarb [14] 5(2) 31/45 15/5 yr —
Cochran [56] 5(4) 36–44 9 mo–8 yr —
Skworc [57] 5(3) 51–61 4 mo–8 yr Plaque-like PrP aggregates with droplet-like
structures
Beck [58] 5(1) 45 .4 yr —
Mead [59] 5(5) 34–63 6 mo–12 yr Kuru-like plaques, PrP deposition
Oda [60] 6(6) 25–36 4–10 yr PrP plaques
Capellari [61] 6(3) 31–38 4–10 yr Elongated PrP patches
King [62] 6(2) 31/37 8/15 yr Dense patches of PrP deposits
Gelpi [63] 6(1) 65 4 yr PrP globules
Kovacs [64] 6(2) 33/35 3/3 yr Diffuse PrP deposits
Collinge [65], King [62] 6(28) 22–53 1–18 yr PrP patches/amyloid
Owen [66] 6(1) middle age — —
Goldfarb [14] 7(6) 23–35 — —
Mizushima [67] 7(1) 29 4–13 yr PrP plaques
Dermaut [68] 7(3) 24–32 11–17 yr Elongated PrP deposits
Lewis [69] 7(1) 29 16 yr Patchy PrP deposits
Wang [70] 7(1) 44 4 yr —
Goldfarb [14] 8(4) 35–55 3 mo–5 yr Multicentric (GSS) plaques
Goldfarb [71] 8(4) 37–46 6 mo–13 yr Kuru-like and multicentric amyloid plaques
Van Gool [72], Stam [73] 8(6) 21–54 1–7 yr Globular PrP deposits
Laplanche [74] 8(10) 21–42 15 mo–7 yr Kuru and multicentric plaques
Owen [75] 9(1) 53 2 yr —
Duchen [76] 9(1) 55 2.5 yr Amyloid PrP plaques
Krasemann [77] 9(1) 32 — —
doi:10.1371/journal.ppat.1000390.t002
Prion Octarepeat Expansion and Copper
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new studies of expanded mouse PrP suggest that OR inserts
actually decrease amyloid production [17].
The OR length also correlates with the progression of prion
disease. Expansions of up to four additional repeats gives the
phenotype of familial Creutzfeldt-Jakob disease (fCJD), character-
ized by PrPSc deposits in the cerebral cortex and associated
dementia [5]. For OR domains containing more than four inserts,
the presentation is consistent with Gerstmann-Straussler-Schein-
ker disease (GSS), in which deposits are concentrated in the
cerebellum and individuals suffer from ataxia. Amyloid is common
in GSS but our review of disease associated with OR expansion,
regardless of length, finds most cases reporting plaques and
amyloid (Table 2).
Progressive elongation of the OR domain leads to alterations of
PrP’s molecular properties, with influence on the tendency to
aggregate, but there must be an additional mechanism responsible
for the sudden and profound shift in age of onset observed
between four and six inserts. As derived from data in Table 2, the
average age of onset for four, five and six inserts is 64, 47 and 34,
respectively. Thus, addition of two repeats lowers the onset age by
27 years. Sequence analysis of the OR domain suggests that both
component 3 and component 1 coordination are physiologically
important [22]. Component 3 coordination requires four OR His
residues, a count that is almost perfectly conserved for all
mammalian species (several species have five repeats). Alterna-
tively, component 1 coordination does not depend on the number
Figure 5. The relationships among OR length, onset age, and copper binding properties. (A) Onset age for individual cases as a function
of extra octarepeat inserts. Note that wild-type corresponds to four repeats, so three inserts corresponds to seven total repeat segments, as in
Figures 3 and 4. The horizontal line represents 55.5 years of age and the vertical line separates four and five inserts (separators determined by CART
analysis). For all cases with four or fewer inserts (e.g., up to eight total repeats), onset age is more than 55.5 years; for five inserts and longer, 96% of
the cases exhibit onset age younger than 55.5 years. (B) Parallel box plot of the data in (A), with the number of individuals in each group given at the
top. Blue circles are outliers. (C) F test results for all pairwise comparisons based on disease onset age. Cells in blue correspond to significant pairwise
differences, thus establishing groupings in onset age for 1–4 OR inserts (late onset) and for 5–8 inserts (early onset). (D) Average onset age, with
standard deviation (blue circles, left axis), and component 1 coordination (orange diamonds and red squares, right axis, for 3.0 and 4.0 equivalents
Cu2+, respectively) as a function of extra octarepeat inserts. At both copper concentrations, component 1 coordination drops suddenly at
approximately the same OR length threshold as average onset age.
doi:10.1371/journal.ppat.1000390.g005
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of repeat modules but instead on the specific HGGGW segment
within each repeat. Again, this sequence is completely conserved
(except for the third Gly, which is Ser in mouse). Our data
demonstrate a profoundly shifted equilibrium between component
3 and component 1 coordination for an OR domain of eight or
more repeats (four or more inserts) that directly correlates with the
observed lowering in onset age.
These findings point to altered copper binding in lowering the
onset age for prion disease. We consider three possible causes.
First, loss of component 1 coordination may lead to enhanced
redox stress. As analyzed in our papers and elsewhere, component
1 coordination stabilizes copper in the Cu2+ oxidation state
[21,26]. Without complexation, copper cycles between Cu+ and
Cu2+, contributing to the production of reactive oxygen species.
Copper concentrations vary significantly in the synaptic space, a
region of high PrP expression. At rest, synaptic copper
concentrations are approximately 3.0 uM [36]. However, upon
neuronal depolarization, copper is released from the presynaptic
surface and the concentration elevates to approximately 250 uM
[37]. The resting concentration is below the component 1
dissociation constant of 10 uM, indicating that component 3
coordination dominates. However, as the copper concentration
rises, PrP reorganizes to take up Cu2+ in the component 1 mode.
Thus, redox protection emerges at high copper levels. For PrP
with more than four inserts, transition to component 1
coordination is inhibited, as indicated by the data in Figure 3,
resulting in a loss of copper redox suppression. Also, with
expanded OR domains showing a 10-fold increase in copper
affinity, the off-rate allowing the component 3 to component 1
transition may be kinetically sluggish.
Another possibility is that an expanded OR domain interferes
with the ability of PrPC to interact with binding partners on the
cell surface. Transgenic mice with alterations of the intervening
sequence between the PrP OR domain and the folded C-terminus
show significant neuronal degeneration [38,39]. Current thinking
suggests that PrPC interacts in a bivalent fashion with a receptor
that plays a role involving cellular signaling or regulation. A
possible binding partner candidate is the low-density liproprotein
receptor related-protein 1, LRP1 [40]. Interaction with LRP1 is
required for copper mediated PrPC endocytosis, and either
elimination of the OR domain or elongation to 14 total repeats
completely halts PrPC cycling. These findings point to a copper-
dependent conformational change in the OR domain consistent
with the component 3 to component 1 transition.
The third possibility considers the role of copper in the
conversion of PrPC to PrPSc. Using protocols for producing
synthetic prions from recombinant mouse PrP, Bocharova et al.
showed that Cu2+ increases the lag time for conversion to amyloid
[41], an effect similar to that observed in the Sup35 chimera with
eight repeats [28]. At a 1:1 copper to protein ratio, influence on
the lag time was minimal. However, a 10-fold higher copper
concentration resulted in a lag time increase of over 100%.
Copper also inhibited polymerization of PrP(89–230), lacking the
OR domain, but the effect was less pronounced. The high ratio of
copper required to inhibit amyloid suggests that component 1
coordination is effective at protecting against polymerization. As
noted above, the 8 OR Sup35 construct exhibited increasing lag
times at near saturating copper levels [28]. In this scenario, PrPC
with eight or more repeats resists component 1 coordination and is
therefore more susceptible than wild-type to misfolding as
amyloid. This is certainly consistent with the widespread amyloid
observed in GSS resulting from repeat inserts.
In summary, our findings demonstrate a very strong relationship
between changes in copper binding properties and early onset
prion disease. The role of the octarepeats in prion disease is
enigmatic. Although the OR domain is not part of the protease
resistant scrapie particle, it nevertheless modulates disease
progression. The studies here point to contributing factors in
prion neurodegeneration, and suggest either loss of PrPC copper
protein function or loss of copper-mediated protection against
conversion to PrPSc.
Materials and Methods
Peptide Synthesis and Purification
All peptides were synthesized using fluorenylmethoxycarbonyl
(Fmoc) methods, as previously described [27,42]. N-terminal
acetylation and C-terminal amidation were included to avoid non-
native backbone charges. Peptides were purified by reverse-phase
HPLC and characterized by mass spectrometry.
Protein Expression and Purification
Syrian Hamster PrP (rPrP(23–231)) was expressed in the
pET101 vector (Invitrogen) in E. coli BL21 Star (DE3) cells
(Invitrogen), as previous described [29]. The protein was
solubilized from inclusion bodies with 8 M urea (pH 8) and
flowed over a nickel charged immobilized metal affinity chroma-
tography (IMAC) column. The protein was eluted from the
column with pH 4.5 urea. Protein folding was achieved by raising
the pH to 8.5 and desalting with a column of Sephadex G-25
(HiPrep, Amersham). The folded protein was then repurfied by
HPLC, characterized by mass spectrometry and lyophilized.
Correct protein fold was confirmed by circular dichroism. As
previously described, mutant mouse PrP with a total of nine
repeats (rPrP+5OR) was generated by multiple rounds of PCR
based mutagenesis followed by expression using the pET23 vector
[43]. Recombinant PrP+5OR was purified using a copper charged
IMAC column [44]. Additional purification and characterization
followed treatments similar to those applied to rPrP(23–231).
Although both hamster and mouse sequences were used, we note
that amino acid sequences in the copper binding segments and
measured EPR, affinity and coordination modes are equivalent
between the two wild-type (four repeat) proteins.
Figure 6. Three-dimensional model of PrP with eight total
repeats (four inserts) coordinated to two equivalents of Cu2+ in
the component 3 mode. (Note that N-terminal residues 23–59 are
not shown.) Results presented here demonstrate that this structure is
persistent and, in contrast to wild-type PrP, resists transitioning to
component 1 coordination (Figure 1).
doi:10.1371/journal.ppat.1000390.g006
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Electron Paramagnetic Resonance (EPR) Spectroscopy
All samples were prepared with buffer containing 37.5 mM
MOPS and 18.75% glycerol (v/v), as a cryoprotectant, with pH
adjusted to 7.4 [42]. X-band spectra (frequency of 9.43 GHz,
microwave power of 1 mW and modulation amplitude of 5.0 G)
were acquired at 125 K using a Bruker EMX spectrometer with
an SHQ cavity (Bruker) and a variable temperature controller.
Sample spectra were fit to basis spectra using non-negative least-
squares (NNLS) routines in the Matlab program suite, as
previously described [19].
Structure Calculations
Calculations for two equivalents of copper loaded into eight
octarepeats as component 3 were calculated using the CYANA
torsional dynamics program [45]. The copper ions were placed
2.01A˚ from the Nd atom of four histidine residues. Two copper
ions were modeled into the sequence (PHGGGWGQ)8GGGTH.
The first four histidine residues were linked to the first copper ion
and the second copper ion was bound to the next four histidine
residues. Calculations were performed that maintained fixed
peptide bond distances and angles. Upper and lower limit distance
restraints between the copper atom and the histidine residues were
used to calculate the model structure. 100 structures were
calculated and the lowest energy conformer was retained. The
model was then linked to PDB coordinates from PrP(97–231) to
create the full-length model structure [46].
Statistical Analysis
For a formal analysis of the relationship between the number of
octarepeat inserts and the onset age, we used a standard one-way
ANOVA model in which the independent variable corresponded
to the number of repeats (treated as a categorical variable) and the
dependent variable corresponded to the onset age. To account for
multiplicities, multiple comparisons were performed using Tukey’s
adjustment [33]. Other data-analysis tools employed include
classification and regression trees (CART) [34], which were used
to confirm the results of the ANOVA model and to determine the
separating age between early and late-onset disease, and
polynomial regression, which served to strengthen the results from
the ANOVA model by treating the number of octarepeats
quantitatively. All calculations were performed in the statistical
computing environment R (http://www.r-project.org). Comple-
mentary analyses, arriving at similar conclusions using nonpara-
metric regression, the bootstrap, and Bayesian change-point
modeling, are available in the online Protocol S1.
Supporting Information
Protocol S1 Statistical analysis using nonlinear regression and
Bayesian change point models. These findings provide additional
support for the relationship between OR length and onset age, and
also reveal evidence of shortened disease duration in cases of eight
or more inserts.
Found at: doi:10.1371/journal.ppat.1000390.s001 (0.20 MB PDF)
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